As of 30 Sep 2025, 31 institutional investors reported holding 2,765,928 shares of Immix Biopharma, Inc. - Common Stock (IMMX).
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 0 | $0 | -$51,259 | $5.64 | 0 |
| 2025 Q3 | 2,765,928 | $5,781,309 | +$912,475 | $2.09 | 31 |
| 2025 Q2 | 2,262,228 | $4,682,595 | -$1,044,152 | $2.07 | 23 |
| 2025 Q1 | 2,918,442 | $4,902,496 | +$70,568 | $1.68 | 22 |
| 2024 Q4 | 2,870,949 | $6,315,600 | -$1,857,746 | $2.20 | 22 |
| 2024 Q3 | 4,094,667 | $6,102,781 | -$618,015 | $1.49 | 26 |
| 2024 Q2 | 4,429,414 | $8,774,511 | -$596,023 | $1.98 | 29 |
| 2024 Q1 | 5,064,965 | $15,545,138 | +$11,322,303 | $3.07 | 32 |
| 2023 Q4 | 18,500 | $128,020 | +$128,020 | $6.92 | 1 |
| 2023 Q3 | 405,051 | $1,385,659 | -$649,847 | $3.42 | 16 |
| 2023 Q2 | 633,819 | $1,705,059 | +$114,957 | $2.69 | 17 |
| 2023 Q1 | 400,796 | $729,846 | -$97,971 | $1.82 | 12 |
| 2022 Q4 | 440,400 | $1,010,250 | +$269,050 | $2.29 | 17 |
| 2022 Q3 | 298,959 | $406,000 | +$156,568 | $1.36 | 7 |
| 2022 Q2 | 183,385 | $475,000 | +$120,003 | $2.59 | 6 |
| 2022 Q1 | 146,485 | $352,000 | -$5,020,392 | $2.39 | 7 |
| 2021 Q4 | 1,538,439 | $5,473,200 | +$3,457,183 | $3.56 | 11 |